Oncology Institute Inc (ticker: TOI) is a premier healthcare organization dedicated to transforming cancer care through its extensive network of specialized clinics and innovative treatment methodologies. The company leverages advanced technologies and personalized care strategies to enhance patient outcomes, while also prioritizing clinical trials and collaborations with leading research institutions. As the demand for advanced cancer therapies grows, TOI is strategically positioned to capitalize on this market trend, underpinned by a robust pipeline and a deep reservoir of oncology expertise, making it an attractive investment opportunity in the evolving healthcare sector.
| Revenue (TTM) | $545.76M |
| Gross Profit (TTM) | $82.50M |
| EBITDA | $-25.91M |
| Operating Margin | -4.42% |
| Return on Equity | -652.00% |
| Return on Assets | -12.30% |
| Revenue/Share (TTM) | $5.54 |
| Book Value | $-0.16 |
| Price-to-Book | 0.76 |
| Price-to-Sales (TTM) | 1.06 |
| EV/Revenue | 1.104 |
| EV/EBITDA | 8.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 41.20% |
| Shares Outstanding | $99.98M |
| Float | $87.32M |
| % Insiders | 18.19% |
| % Institutions | 45.82% |
Volatility is currently contracting
One area of Wall Street that investors might want to start buying are strong, best-in-class, cheap stocks trading under $10 a share in July and throughout the rest of 2026.
CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed.
Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.
The Oncology Institute (TOI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tom Yeung here with your Sunday Digest . In 2025, two professors wanted to see whether ChatGPT made people less creative.
The average of price targets set by Wall Street analysts indicates a potential upside of 38.1% in The Oncology Institute (TOI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TORONTO, May 31, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV: TOI), acting through its subsidiary TSS Europe B.V. (“TSS”), today submitted a revised non-binding indicative proposal to acquire ReadyTech Holdings Limited (ASX: RDY) (“ReadyTech”) by way of a scheme of arrangement for cash consideration of $2.00 per share (the “Scheme Consideration”), or in the alternative, an off-market takeover bid with a 50.1% minimum acceptance condition at a cash consideration of $1.75 per share (the "Takeover Consideration") (together, the "Revised Proposal")1. All references herein to currency are in Australian dollars.
CERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D.
Topicus.com Inc. (TOI:CA) Shareholder/Analyst Call Prepared Remarks Transcript
CERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the B.
